Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
US8293744B2 · kind B2 · utility
2Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2010 |
| Grant date | Oct 23, 2012 |
| Priority date | — |
| Expiry date | Apr 13, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to heterocyclic fused cinnoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.